Pain News and Research

Latest Pain News and Research

Evotec signs research collaboration and licensing deal with Debiopharm Group

Evotec AG announced today a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

2 Apr 2014

Study examines complications in adult tonsillectomies and impact on health care expenditures

A study released today of 36,210 adult tonsillectomy patients finds that 20 percent will have a complication, offering valuable new insights to a decades long discussion. The study, featured in the April 2014 issue of Otolaryngology-Head and Neck Surgery, examines the prevalence of complications in adult tonsillectomies and the impact on health care expenditures.

2 Apr 2014

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

1 Apr 2014

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Supreme Court has granted the Company's COPAXONE® certiorari petition and will hear its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (the "'808 patent").

1 Apr 2014

Over three-quarters of Americans favor root canal treatments

Fewer Americans fear root canal treatment, according to a recent survey by the American Association of Endodontists. Just over half of those surveyed, 54 percent, said root canals make them apprehensive, down from 60 percent in 2013, and the lowest numbers reported since the AAE began its annual survey in 2011.

1 Apr 2014

Antibe Therapeutics closes previously announced non-brokered private placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") has closed its previously announced non-brokered private placement raising gross proceeds of $3,015,398 (the "Offering") on the sale of 5,025,664 Common Shares of the Corporation.

1 Apr 2014

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin.

1 Apr 2014

Early rehabilitation improves neurofunctional outcome after surgery in children with spinal tumors

In children, primary spinal tumors comprise 4% of all tumors from the central nervous system. Spinal tumors can present with a variety of clinical signs and symptoms in children such as pain followed by motor regression, gait disturbance, sphincter dysfunction, sensory symptoms, torticollis, and kyphoscoliosis.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Veterans struggle with mental health problems

More than half of the 2.6 million Iraq and Afghanistan veterans say they struggle with physical or mental health problems as a result of their service and feel detached from civilian life, according to a poll conducted by The Washington Post and the Kaiser Family Foundation.

1 Apr 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, today announced that it has filed a 510(k) premarket submission for the APPY1 Test. Venaxis has requested concurrent de novo determination and 510(k) clearance from the U.S. Food and Drug Administration.

31 Mar 2014

First Edition: March 31, 2014

Today's early morning highlights from the major news organizations offer assessments of the administration's campaign to get people signed up for health care and a look at the issues going forward after today's deadline for most enrollments.

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd., based in Seoul, South Korea for the distribution of Probi´s gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014.

31 Mar 2014

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

31 Mar 2014

Spouses who express emotions have better sexual, psychological and relational well-being

Spouses who regulate their emotions together in a satisfactory manner are more fulfilled sexually, psychologically, and relationally, among couples in which the woman has provoked vestibulodynia (PVD), also known as "vulvar vestibulitis".

31 Mar 2014

$Choosing better treatment for ankle fractures$

Choosing better treatment for ankle fractures

Many people associate ankle fractures with sports, but you don't have to be an athlete to develop a serious ankle injury. Ankle fractures, in which there is a partial or complete break in a bone, can happen to anyone. People can break an ankle after a fall, car accident or twisting injury.

29 Mar 2014

Pain News and Research

Latest Pain News and Research

Evotec signs research collaboration and licensing deal with Debiopharm Group

Study examines complications in adult tonsillectomies and impact on health care expenditures

Discovery could lead to new therapies for people with celiac disease

U.S. Supreme Court agrees to hear Teva Pharmaceutical's appeal related to COPAXONE patent

Over three-quarters of Americans favor root canal treatments

Antibe Therapeutics closes previously announced non-brokered private placement

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Early rehabilitation improves neurofunctional outcome after surgery in children with spinal tumors

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Veterans struggle with mental health problems

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Venaxis files 510(k) premarket submission with FDA for APPY1 Test

First Edition: March 31, 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Dongkook Pharmaceutical to launch Probi Mage dietary supplement in South Korea

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

Spouses who express emotions have better sexual, psychological and relational well-being

Choosing better treatment for ankle fractures

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Pain News and Research

Latest Pain News and Research

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in